HOME Top Market Reports North American Nuclear Medicine/Radiopharmaceuticals Market by Type (Diagnostic (SPECT - Technetium, PET- F-18), Therapeutic (Beta Emitters – I-131, Alpha Emitters, Brachytherapy – Y-90)), by Application (Oncology, Cardiology) - Forecasts to 2020

North American Nuclear Medicine/Radiopharmaceuticals Market by Type (Diagnostic (SPECT - Technetium, PET- F-18), Therapeutic (Beta Emitters – I-131, Alpha Emitters, Brachytherapy – Y-90)), by Application (Oncology, Cardiology) - Forecasts to 2020

By: marketsandmarkets.com
Publishing Date: March 2016
Report Code: BT 4151

 

  Speak to Analyst Enquiry Before Buying  
purchase report
download pdf  request for customisation


The North American nuclear medicine/radiopharmaceuticals market is poised to reach USD 2.98 Billion by 2020, growing at a CAGR of 8.6% during the forecast period of 2015 to 2020. The growth of the overall North American Nuclear Medicine market can be contributed to increasing preference for SPECT and PET scans, alpha radioimmunotherapy-based targeted cancer treatment, advances in radiotracers, growing incidence of cancer and CVDs, and rising awareness about the effective use of radiopharmaceuticals. In the coming years, U.S. is expected to witness the highest growth rate in the North American Nuclear Medicine market. The U.S. is also expected to account for the largest share of the North American Nuclear Medicine market. The large share and high growth in the U.S. can be attributed to the focus on domestic production of Mo-99, the approval of new radiopharmaceuticals by the FDA in the U.S., FDA approval for alpha emitter, growing focus on therapeutic nuclear medicine as an alternative treatment in oncology, and growing incidence of thyroid cancer.

The report segments the North American Nuclear Medicine market based on type of isotope. The North American radiopharmaceuticals market comprises of diagnostic and therapeutic radioisotopes. The diagnostic radioisotopes segment is expected to account for the largest share of the North American nuclear medicine market in 2015. This is attributed to increasing patient population, introduction of new and effective radioisotopes, and increase in awareness about nuclear medicine.

The report segments the North American nuclear medicine market based on application area. The North American nuclear medicine market comprises of SPECT, PET and therapeutic applications. The SPECT applications segment is expected to account for the largest share of the North American nuclear medicine market in 2015. This is attributed to the rising demand for minimally invasive surgeries and targeted radiotherapy, increasing preference for SPECT, advances in SPECT radiotracers, and growing incidence of cancer and CVDs, among others.

Some of the key players in the North American nuclear medicine market include Cardinal Health Inc. (U.S.), Mallinckrodt plc (Ireland), GE Healthcare (U.K.), Lantheus Medical Imaging, Inc. (U.S.), Bayer Healthcare (Germany), Bracco Imaging S.p.A (Italy), Eczacibasi-Monrol Nuclear Products (Turkey), Nordion, Inc. (Canada), Advanced Accelerator Applications S.A. (France), and IBA Molecular Imaging (Belgium).

Target Audience of the North American nuclear medicine Market 

  • Radiopharmaceutical/Radioisotope Manufacturers and Distributors
  • Healthcare Institutions (Hospitals, Medical Schools, and Outpatient Clinics)
  • Research and Consulting Firms
  • Research Institutes
  • Venture Capitalists
  • Contract Manufacturing Organizations (CMOs)
  • Contract Research Organizations (CROs)

Scope of the Report:

This research report categorizes the North American radiopharmaceuticals market into the following segments:

North American Nuclear Medicine Market, by Type

  • Diagnostic
    • SPECT Radiopharmaceuticals
      • Tc-99
      • Tl-201
      • Ga-67
      • I-123
      • Other SPECT radioisotopes
    • PET Radiopharmaceuticals
      • F-18
      • Ru-82
      • Other PET radioisotopes
  • Therapeutic
    • Beta Emitters
      • I-131
      • Sm-153
      • Rh-186
      • Y-90
      • Lu-177
      • Other Beta emitters
    • Alpha Emitters
      • Ra-223
    • Brachytherapy
      • I-125
      • Ir-192
      • Pa-103
      • Cs-131
      • Other brachytherapy radioisotopes

North American Nuclear Medicine Market, by Application

  • Diagnostic
    • SPECT
      • Cardiology
      • Lymphoma
      • Thyroid
      • Neurology
      • Other SPECT applications
    • PET
      • Oncology
      • Cardiology
      • Neurology
      • Other PET applications
  • Therapeutic
    • Thyroid
    • Bone Metastasis
    • Lymphoma
    • Endocrine Tumors
    • Other therapeutic applications

North American Nuclear Medicine Procedural Volumes

  • Diagnostic
    • SPECT Radiopharmaceuticals
    • PET Radiopharmaceuticals
  • Therapeutic
    • Beta Emitters
    • Alpha Emitters
    • Brachytherapy

North American Nuclear Medicine Market, by Country

  • U.S.
  • Canada

Available Customizations

With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to 5), inclusive of:

  • Business Overview
  • Financial Information
  • Product Portfolio
  • Developments (Last 3 years)

Note: Some companies in the market are privately owned and their revenues are not available in the public domain. Hence, revenues for privately owned companies will not be included in their profile. Also, company developments that are not reported in the public domain will not be included.

Table of Contents

1 Introduction (Page No. - 19)
    1.1 Objectives of Study
    1.2 North American Radiopharmaceuticals Market Definition
    1.3 North American Radiopharmaceuticals Market Scope
           1.3.1 Markets Covered
           1.3.2 Years Considered for the Study
    1.4 Currency
    1.5 Limitations
    1.6 Stakeholders

2 Research Methodology (Page No. - 22)
    2.1 Research Methodology Steps
    2.2 Secondary and Primary Research Methodology
           2.2.1 Secondary Research
           2.2.2 Primary Research
                    2.2.2.1 Key Industry Insights
                    2.2.2.2 Key Data From Primary Sources
                    2.2.2.3 Key Insights From Primary Sources
    2.3 North American Radiopharmaceuticals Market Size Estimation Methodology
    2.4 Research Design
    2.5 North American Radiopharmaceuticals Market Data Validation and Triangulation
    2.6 Assumptions for the Study

3 Executive Summary (Page No. - 31)
    3.1 Introduction
    3.2 Current Scenario
    3.3 Future Outlook

4 Premium Insights (Page No. - 35)
    4.1 North American Nuclear Medicine Market
    4.2 North American Nuclear Medicine Diagnostic Market, By Therapeutic and Spect Application
    4.3 North American Nuclear Medicine Market, By Country
    4.4 North American Nuclear Medicine Market, By Type (2015 vs 2020)

5 Market Overview (Page No. - 39)
    5.1 Introduction
    5.2 North American Radiopharmaceuticals Market Segmentation
    5.3 North American Radiopharmaceuticals Market Dynamics
           5.3.1 Drivers
                    5.3.1.1 Increasing Preference for Spect and PET Scans
                    5.3.1.2 Alpha Radioimmunotherapy-Based Targeted Cancer Treatment
                    5.3.1.3 Advances in Radiotracers
                    5.3.1.4 Growing Incidence of Cancer and Cvds
                    5.3.1.5 Rising Awareness About the Effective Use of Radiopharmaceuticals in Various Applications
           5.3.2 Restraints
                    5.3.2.1 Requirement of High Capital Investments to Limit the Procurement of Scanners
                    5.3.2.2 Shorter Half-Life of Radiopharmaceuticals
                    5.3.2.3 Stringent Regulatory Guidelines and Good Manufacturing Practices
                    5.3.2.4 Competition From Conventional Diagnostic Procedures
           5.3.3 Opportunities
                    5.3.3.1 Upcoming Radioisotopes
                    5.3.3.2 Alternative Diagnostic Radiopharmaceutical Solutions
                    5.3.3.3 Cyclotron-Based Production
                    5.3.3.4 Use of Radiopharmaceuticals in Neurological Applications
           5.3.4 Challenges
                    5.3.4.1 Shutdown of Nuclear Reactors to Impact Production of Radioisotopes

6 North American Nuclear Medicine Market: Pipeline Assessment (Page No. - 49)
    6.1 Introduction
    6.2 Diagnostic Radioisotopes
    6.3 Therapeutic Radioisotopes

7 North American Nuclear Medicine Market, By Type (Page No. - 61)
    7.1 Introduction
    7.2 Diagnostic Nuclear Medicine/Radiopharmaceuticals
           7.2.1 Spect Radiopharmaceuticals
                    7.2.1.1 Technetium-99m
                    7.2.1.2 Thallium-201
                    7.2.1.3 Gallium-67
                    7.2.1.4 Iodine-123
                    7.2.1.5 Other Spect Isotopes
           7.2.2 PET Radiopharmaceuticals
                    7.2.2.1 Fluorine-18
                    7.2.2.2 Rubidium-82
                    7.2.2.3 Other PET Isotopes
    7.3 Therapeutic Nuclear Medicine/Radiopharmaceuticals
           7.3.1 Beta Emitters
                    7.3.1.1 Iodine-131
                    7.3.1.2 Yttrium-90
                    7.3.1.3 Samarium-153
                    7.3.1.4 Rhenium-186
                    7.3.1.5 Lutetium-177
                    7.3.1.6 Other Beta Emitter Isotopes
           7.3.2 Alpha Emitters
                    7.3.2.1 Radium-223
           7.3.3 Brachytherapy
                    7.3.3.1 Iodine-125
                    7.3.3.2 Iridium-192
                    7.3.3.3 Palladium-103
                    7.3.3.4 Cesium-131
                    7.3.3.5 Other Brachytherapy Isotopes

8 North American Nuclear Medicine Market, By Application (Page No. - 89)
    8.1 Introduction
    8.2 Diagnostic Applications
           8.2.1 Spect Applications
                    8.2.1.1 Cardiology
                    8.2.1.2 Lymphoma
                    8.2.1.3 Neurology
                    8.2.1.4 Thyroid
                    8.2.1.5 Other Spect Applications
           8.2.2 PET Applications
                    8.2.2.1 Oncology
                    8.2.2.2 Cardiology
                    8.2.2.3 Neurology
                    8.2.2.4 Other PET Applications
    8.3 Therapeutic Applications
           8.3.1 Thyroid
           8.3.2 Bone Metastasis
           8.3.3 Lymphoma
           8.3.4 Endocrine Tumors
           8.3.5 Other Therapeutic Applications

9 North American Nuclear Medicine Market for Procedural Volume (Page No. - 112)
    9.1 Introduction
    9.2 Diagnostic Nuclear Medicine/Radiopharmaceuticals Market for Procedural Volume
           9.2.1 Spect Radiopharmaceuticals
           9.2.2 PET Radiopharmaceuticals
    9.3 Therapeutic Nuclear Medicine/Radiopharmaceuticals Market for Procedural Volume
           9.3.1 Beta Emitters
           9.3.2 Brachytherapy

10 North American Nuclear Medicine Market, By Country (Page No. - 118)
     10.1 Introduction
     10.2 Diagnostic Market
             10.2.1 North America
                        10.2.1.1 U.S.
                                     10.2.1.1.1 Domestic Production of Mo-99 in the U.S.
                                     10.2.1.1.2 Approval of New Radiopharmaceuticals By Fda
                        10.2.1.2 Canada
                                     10.2.1.2.1 Extension of Operations at the Canadian National Research Universal (NRU) Reactor
                                     10.2.1.2.2 Alternative Medical Isotope Technologies in Canada
     10.3 Therapeutic Market
             10.3.1 North America
                        10.3.1.1 U.S.
                                     10.3.1.1.1 Fda Approval for Alpha Emitter
                                     10.3.1.1.2 Therapeutic Nuclear Medicine - Alternative Treatment Choice in Oncology
                                     10.3.1.1.3 Growing Incidence of Thyroid Cancer
                        10.3.1.2 Canada
                                     10.3.1.2.1 Expertise in Isotope Production
                                     10.3.1.2.2 Government Initiatives to Increase the Number of Nuclear Medicine Treatment Centers
                                     10.3.1.2.3 High Incidence of Cancer

11 Competitive Landscape (Page No. - 136)
     11.1 Overview
     11.2 Competitive Situation and Trends
             11.2.1 Introduction
             11.2.2 Agreements, Collaborations, Contracts, and Partnerships
             11.2.3 Marketing and Promotions
             11.2.4 New Product Launches
             11.2.5 Expansions
             11.2.6 Acquisitions
             11.2.7 Other Strategies
     11.3 North American Nuclear Medicine Market: Empirical Assessment of Growth Strategies
             11.3.1 Route to Strategic Growth: Organic and Inorganic Growth Strategies
             11.3.2 Organic Growth Strategies
             11.3.3 Inorganic Growth Strategies

12 Company Profiles (Page No. - 147)
(Overview, Financials, Products & Services, Strategy, & Developments)*
     12.1 Introduction
     12.2 Cardinal Health, Inc.
     12.3 Mallinckrodt PLC
     12.4 GE Healthcare
     12.5 Lantheus Medical Imaging, Inc.
     12.6 Bayer Healthcare
     12.7 Bracco Imaging S.P.A
     12.8 Eczacibasi-Monrol Nuclear Products
     12.9 Nordion, Inc.
     12.10 Advanced Accelerator Applications S.A.
     12.11 IBA Molecular Imaging

*Details on Financials, Product & Services, Strategy, & Developments Might Not Be Captured in Case of Unlisted Companies.

13 Appendix (Page No. - 169)
     13.1 Discussion Guide
     13.2 Available Customizations
     13.3 Knowledge Store: Marketsandmarkets’ Subscription Portal
     13.4 Introducing RT: Real-Time Market Intelligence
     13.5 Related Reports


List of Tables (92 Tables)

Table 1 Alpha Radioimmunotherapy-Based Targeted Cancer Treatment Driving Market Growth
Table 2 Requirement of High Capital Investments and Short Half-Life of Radiopharmaceuticals Restraining Market Growth
Table 3 Potential Radioisotopes in the Pipeline to Offer Significant Growth Opportunities to Market Players
Table 4 Shutdown of Nuclear Reactors is A Major Challenge in This Market
Table 5 Details of Radiopharmaceuticals for Upcoming Diagnostic Applications
Table 6 Details of Radiopharmaceuticals for Upcoming Therapeutic Applications
Table 7 North American Nuclear Medicine Market Size, By Type, 2013-2020 (USD Million)
Table 8 North America: Diagnostic Nuclear Medicine/Radiopharmaceuticals Market Size, By Country, 2013-2020 (USD Million)
Table 9 North America: Diagnostic Nuclear Medicine/Radiopharmaceuticals Market Size, By Type, 2013-2020 (USD Million)
Table 10 North America: Spect Nuclear Medicine/Radiopharmaceuticals Market Size, By Country, 2013-2020 (USD Million)
Table 11 North America: Spect Nuclear Medicine/Radiopharmaceuticals Market Size, By Isotope, 2013-2020 (USD Million)
Table 12 North America: Technetium-99m Nuclear Medicine/Radiopharmaceuticals Market Size, By Country, 2013-2020 (USD Million)
Table 13 North America: Thallium-201 Nuclear Medicine/Radiopharmaceuticals Market Size, By Country, 2013-2020 (USD Million)
Table 14 North America: Gallium-67 Nuclear Medicine/Radiopharmaceuticals Market Size, By Country, 2013-2020 (USD Million)
Table 15 North America: Iodine-123 Nuclear Medicine/Radiopharmaceuticals Market Size, By Country, 2013-2020 (USD Million)
Table 16 North America: Other Spect Nuclear Medicine/Radiopharmaceuticals Market Size, By Country, 2013-2020 (USD Million)
Table 17 North America: PET Nuclear Medicine/Radiopharmaceuticals Market Size, By Country, 2013-2020 (USD Million)
Table 18 North America: PET Nuclear Medicine/Radiopharmaceuticals Market Size, By Isotope, 2013-2020 (USD Million)
Table 19 North America: Fluorine-18 Nuclear Medicine/Radiopharmaceuticals Market Size, By Country, 2013-2020 (USD Million)
Table 20 North America: Rubidium-82 Nuclear Medicine/Radiopharmaceuticals Market Size, By Country, 2013-2020 (USD Million)
Table 21 North America: Other PET Nuclear Medicine/Radiopharmaceuticals Market Size, By Country, 2013-2020 (USD Million)
Table 22 North America: Therapeutic Nuclear Medicine/Radiopharmaceuticals Market Size, By Country, 2013-2020 (USD Million)
Table 23 North America: Therapeutic Nuclear Medicine/Radiopharmaceuticals Market Size, By Type, 2013-2020 (USD Million)
Table 24 North America: Beta Emitter Nuclear Medicine/Radiopharmaceuticals Market Size, By Country, 2013-2020 (USD Million)
Table 25 North America: Beta Emitter Nuclear Medicine Market Size, By Isotope, 2013-2020 (USD Million)
Table 26 North America: Iodine-131 Nuclear Medicine/Radiopharmaceuticals Market Size, By Country, 2013-2020 (USD Million)
Table 27 North America: Yttrium-90 Nuclear Medicine/Radiopharmaceuticals Market Size, By Country, 2013-2020 (USD Million)
Table 28 North America: Samarium-153 Nuclear Medicine/Radiopharmaceuticals Market Size, By Country, 2013-2020 (USD Million)
Table 29 North American Rhenium-186 Nuclear Medicine/Radiopharmaceuticals Market Size, By Country, 2013-2020 (USD Million)
Table 30 North America: Lutetium-177 Nuclear Medicine/Radiopharmaceuticals Market Size, By Country, 2013-2020 (USD Million)
Table 31 North America: Other Beta Emitter Nuclear Medicine/Radiopharmaceuticals Market Size, By Country, 2013-2020 (USD Million)
Table 32 North America: Alpha Emitter Nuclear Medicine/Radiopharmaceuticals Market Size, By Country, 2013-2020 (USD Million)
Table 33 North America: Brachytherapy Nuclear Medicine/Radiopharmaceuticals Market Size, By Country, 2013-2020 (USD Million)
Table 34 North America: Brachytherapy Nuclear Medicine/Radiopharmaceuticals Market Size, By Isotope, 2013-2020 (USD Million)
Table 35 North America: Iodine-125 Nuclear Medicine/Radiopharmaceuticals Market Size, By Country, 2013-2020 (USD Million)
Table 36 North America: Iridium-192 Nuclear Medicine/Radiopharmaceuticals Market Size, By Country, 2013-2020 (USD Million)
Table 37 North America: Palladium-103 Nuclear Medicine/Radiopharmaceuticals Market Size, By Country, 2013-2020 (USD Million)
Table 38 North America: Cesium-131 Nuclear Medicine/Radiopharmaceuticals Market Size, By Country, 2013-2020 (USD Million)
Table 39 North America: Other Brachytherapy Nuclear Medicine/Radiopharmaceuticals Market Size, By Country, 2013-2020 (USD Million)
Table 40 North America: Diagnostic Nuclear Medicine/Radiopharmaceuticals Applications Market Size for Spect Isotopes, By Country, 2013-2020 (USD Million)
Table 41 North America: Diagnostic Nuclear Medicine/Radiopharmaceuticals Applications Market Size for Spect Isotopes, By Type, 2013-2020 (USD Million)
Table 42 North America: Diagnostic Nuclear Medicine/Radiopharmaceuticals Market Size for Cardiology Spect Applications, By Country, 2013-2020 (USD Million)
Table 43 North America: Diagnostic Nuclear Medicine/Radiopharmaceuticals Market Size for Lymphoma Spect Applications, By Country, 2013-2020 (USD Million)
Table 44 North America: Diagnostic Nuclear Medicine/Radiopharmaceuticals Market Size for Neurology Spect Applications, By Country, 2013-2020 (USD Million)
Table 45 North America: Diagnostic Nuclear Medicine/Radiopharmaceuticals Market Size for Thyroid Spect Applications, By Country, 2013-2020 (USD Million)
Table 46 North America: Diagnostic Nuclear Medicine/Radiopharmaceuticals Market Size for Other Spect Applications, By Country, 2013-2020 (USD Million)
Table 47 North America: Diagnostic Nuclear Medicine/Radiopharmaceuticals Market Size for PET Applications, By Country, 2013-2020 (USD Million)
Table 48 North America: Diagnostic Nuclear Medicine/Radiopharmaceuticals Market Size for PET Applications, By Type, 2013-2020 (USD Million)
Table 49 North America: Diagnostic Nuclear Medicine/Radiopharmaceuticals Market Size for Oncology PET Applications, By Country, 2013-2020 (USD Million)
Table 50 North America: Diagnostic Nuclear Medicine/Radiopharmaceuticals Market Size for Cardiology PET Applications, By Country, 2013-2020 (USD Million)
Table 51 North America: Diagnostic Nuclear Medicine/Radiopharmaceuticals Market Size for Neurology PET Applications, By Country, 2013-2020 (USD Million)
Table 52 North America: Diagnostic Nuclear Medicine/Radiopharmaceuticals Market Size for Other PET Applications, By Country, 2013-2020 (USD Million)
Table 53 North American Nuclear Medicine Market Size for Therapeutic Applications, By Country, 2013-2020 (USD Million)
Table 54 North American Nuclear Medicine Market Size for Therapeutic Applications, By Type, 2013-2020 (USD Million)
Table 55 North America: Therapeutic Nuclear Medicine/Radiopharmaceuticals Market Size for Thyroid Applications, By Country, 2013-2020 (USD Million)
Table 56 North America: Therapeutic Nuclear Medicine/Radiopharmaceuticals Market Size for Bone Metastasis, By Country, 2013-2020 (USD Million)
Table 57 North America: Therapeutic Nuclear Medicine/Radiopharmaceuticals Market Size for Lymphoma, By Country, 2013-2020 (USD Million)
Table 58 North America: Therapeutic Nuclear Medicine/Radiopharmaceuticals Market Size for Endocrine Applications, By Country, 2013-2020 (USD Million)
Table 59 North American Nuclear Medicine Market Size for Other Therapeutic Applications, By Country, 2013-2020 (USD Million)
Table 60 North American Nuclear Medicine Market for Procedural Volume, By Type, 2013–2020 (Thousand Units)
Table 61 North American Nuclear Medicine Market for Procedural Volume, By Country, 2013–2020 (Thousand Units)
Table 62 North America: Diagnostic Nuclear Medicine/Radiopharmaceuticals Market for Procedural Volume, By Type, 2013–2020 (Thousand Units)
Table 63 North America: Spect Nuclear Medicine/Radiopharmaceuticals Market for Procedural Volume, By Type, 2013–2020 (Thousand Units)
Table 64 North America: PET Nuclear Medicine/Radiopharmaceuticals Market for Procedural Volume, By Type, 2013–2020 (Thousand Units)
Table 65 North America: Therapeutic Nuclear Medicine/Radiopharmaceuticals Market for Procedural Volume, By Type, 2013–2020 (Thousand Units)
Table 66 North America: Beta Emitters Nuclear Medicine/Radiopharmaceuticals Market for Procedural Volume, By Type, 2013–2020 (Thousand Units)
Table 67 North America: Brachytherapy Nuclear Medicine/Radiopharmaceuticals Market for Procedural Volume, By Type, 2013–2020 (Thousand Units)
Table 68 North American Nuclear Medicine Market Size, By Type, 2013-2020 (USD Million)
Table 69 U.S.: Diagnostic Nuclear Medicine/Radiopharmaceuticals Market Size, By Type, 2013-2020 (USD Million)
Table 70 U.S.: Spect Nuclear Medicine/Radiopharmaceuticals Market Size, By Type, 2013-2020 (USD Million)
Table 71 U.S.: PET Nuclear Medicine/Radiopharmaceuticals Market Size, By Type, 2013-2020 (USD Million)
Table 72 U.S.: Spect Nuclear Medicine/Radiopharmaceuticals Market Size, By Application, 2013-2020 (USD Million)
Table 73 U.S.: PET Nuclear Medicine/Radiopharmaceuticals Market Size, By Application, 2013-2020 (USD Million)
Table 74 Canada: Diagnostic Nuclear Medicine/Radiopharmaceuticals Market Size, By Type, 2013-2020 (USD Million)
Table 75 Canada: Spect Nuclear Medicine/Radiopharmaceuticals Market Size, By Type, 2013-2020 (USD Million)
Table 76 Canada: PET Nuclear Medicine/Radiopharmaceuticals Market Size, By Type, 2013-2020 (USD Million)
Table 77 Canada: Spect Nuclear Medicine/Radiopharmaceuticals Market Size, By Application, 2013-2020 (USD Million)
Table 78 Canada: PET Nuclear Medicine/Radiopharmaceuticals Market Size, By Application, 2013-2020 (USD Million)
Table 79 U.S.: Therapeutic Nuclear Medicine/Radiopharmaceuticals Market Size, By Type, 2013-2020 (USD Million)
Table 80 U.S.: Beta Emitters Nuclear Medicine/Radiopharmaceuticals Market Size, By Type, 2013-2020 (USD Million)
Table 81 U.S.: Brachytherapy Nuclear Medicine/Radiopharmaceuticals Market Size, By Type, 2013-2020 (USD Million)
Table 82 U.S.: Therapeutic Nuclear Medicine/Radiopharmaceuticals Market Size, By Application, 2013-2020 (USD Million)
Table 83 Canada: Therapeutic Nuclear Medicine/Radiopharmaceuticals Market Size, By Type, 2013-2020 (USD Million)
Table 84 Canada: Beta Emitters Nuclear Medicine/Radiopharmaceuticals Market Size, By Type, 2013-2020 (USD Million)
Table 85 Canada: Brachytherapy Nuclear Medicine/Radiopharmaceuticals Market Size, By Type, 2013-2020 (USD Million)
Table 86 Canada: Therapeutic Nuclear Medicine/Radiopharmaceuticals Market Size, By Application, 2013-2020 (USD Million)
Table 87 Agreements, Collaborations, Contracts, and Partnerships, 2013-2016
Table 88 Marketing and Promotions, 2013-2016
Table 89 New Product Launches, 2013-2016
Table 90 Expansions, 2013-2014
Table 91 Acquisitions, 2013-2016
Table 92 Other Strategies, 2013-2016


List of Figures (60 Figures)

Figure 1 North American Radiopharmaceuticals Market Segmentation
Figure 2 North American Radiopharmaceuticals Market: Research Methodology Steps
Figure 3 Key Data From Secondary Sources
Figure 4 Break Down of Primary Interviews: By Company Type, Designation, and Country
Figure 5 North American Radiopharmaceuticals Market Size Estimation Methodology: Bottom-Up Approach
Figure 6 North American Radiopharmaceuticals Market Size Estimation Methodology: Top-Down Approach
Figure 7 Research Design
Figure 8 Data Triangulation Methodology
Figure 9 Therapeutics Market to Witness the Highest Growth Rate From 2015 to 2020
Figure 10 North American Nuclear Medicine Therapeutics Market Share, By Type, 2015 vs 2020
Figure 11 Geographical Snapshot of the North American Nuclear Medicine Market, 2015
Figure 12 North American Nuclear Medicine Spect Applications Market Size, 2015 vs 2020 (USD Million)
Figure 13 Advances in Radiotracers to Propel Market Growth
Figure 14 Thyroid Application Segment Dominates the North American Therapeutic Nuclear Medicine Market in 2015
Figure 15 U.S. to Witness the Highest Growth Rate During the Forecast Period
Figure 16 Diagnostics Segment to Command the Largest Market Share During the Forecast Period
Figure 17 North American Nuclear Medicine Market Segmentation
Figure 18 North American Nuclear Medicine Market: Drivers, Restraints, Opportunities, & Challenges
Figure 19 Clinical Trials for Diagnostic & Therapeutic Radioisotopes, By Phase
Figure 20 Clinical Trials for Diagnostic & Therapeutic Radioisotopes, By Company & Institute
Figure 21 Clinical Trials for Radioisotopes, By Type
Figure 22 Clinical Trials for Diagnostic Radioisotopes, By Subtype
Figure 23 Clinical Trials for Diagnostic Radioisotopes, By Indication
Figure 24 Clinical Trials for Diagnostic Radioisotopes, By Phase
Figure 25 Clinical Trials for Diagnostic Radioisotopes, By Company & Institute
Figure 26 Clinical Trials for Therapeutic Radioisotopes, By Subtype
Figure 27 Clinical Trials for Therapeutic Radioisotopes, By Indication
Figure 28 Clinical Trials for Therapeutic Radioisotopes, By Phase
Figure 29 Clinical Trials for Therapeutic Radioisotopes, By Company & Institute
Figure 30 North American Nuclear Medicine Market Segmentation, By Type
Figure 31 Therapeutic Segment to Grow at the Highest CAGR of 10.0%
Figure 32 PET Segment to Grow at the Highest CAGR of 11.3% During the Forecast Period
Figure 33 Alpha Emitters Segment to Grow at the Highest CAGR of 16.8% During the Forecast Period
Figure 34 North American Diagnostic Nuclear Medicine/Radiopharmaceuticals Applications Market Segmentation
Figure 35 Segmentation of North American Diagnostic Nuclear Medicine/Radiopharmaceuticals Applications Market for Spect Isotopes
Figure 36 U.S. to Grow at the Highest CAGR During the Forecast Period
Figure 37 Neurology Application Segment to Grow at the Highest CAGR of 7.8% During the Forecast Period
Figure 38 Segmentation of North American Diagnostic Nuclear Medicine/Radiopharmaceuticals Applications Market for PET Isotopes
Figure 39 U.S. to Grow at the Highest CAGR During the Forecast Period
Figure 40 Neurology Application Segment to Grow at the Highest CAGR of 12.6% During the Forecast Period
Figure 41 North American Therapeutic Nuclear Medicine/Radiopharmaceuticals Applications Market Segmentation
Figure 42 U.S. to Grow at the Highest CAGR During the Forecast Period
Figure 43 Endocrine Tumors Application Segment to Grow at the Highest CAGR of 10.8% During the Forecast Period
Figure 44 U.S. to Command the Largest Share of the North American Diagnostic Nuclear Medicine/Radiopharmaceuticals Market in 2015
Figure 45 North American Diagnostic Nuclear Medicine/Radiopharmaceuticals Market Overview
Figure 46 U.S. to Command the Largest Share of the North American Therapeutic Nuclear Medicine/Radiopharmaceuticals Market in 2015
Figure 47 North American Therapeutic Nuclear Medicine/Radiopharmaceuticals Market Overview
Figure 48 Top 5 Strategies Adopted By Players Over the Last Three Years (2013-2016)
Figure 49 Battle for Market Share: Agreements, Collaborations, Contracts, and Partnerships Was the Key Strategy (2013 -2016)
Figure 50 Organic & Inorganic Growth Strategies: Industry Trend vs Key Players
Figure 51 Organic Growth Strategies, By Key Player (2013–2016)
Figure 52 Inorganic Growth Strategies, By Key Player (2013–2016)
Figure 53 Product Mix of the Key Players in the Market
Figure 54 Cardinal Health, Inc.: Company Snapshot
Figure 55 Mallinckrodt PLC: Company Snapshot
Figure 56 GE Healthcare: Company Snapshot
Figure 57 Lantheus Medical Imaging, Inc.: Company Snapshot
Figure 58 Bayer Healthcare: Company Snapshot
Figure 59 Nordion, Inc.: Company Snapshot
Figure 60 Advanced Accelerator Applications S.A.: Company Snapshot

The North American nuclear medicine market is expected to reach USD 2.98 Billion in 2020 from USD 1.97 Billion in 2015, growing at a CAGR of 8.6%. . Radiopharmaceuticals are drugs that contain radionuclide-emitting ionizing radiation, used in the nuclear imaging field to diagnose and treat various diseases. The North American nuclear medicine market is segmented on the basis of types, applications, and countries.

The radiopharmaceuticals market, by type is broadly classified into two segments, namely, diagnostic and therapeutic radioisotopes. Radioisotopes in the diagnostic market are further categorized as SPECT and PET; while the therapeutic market is classified into beta emitters, brachytherapy isotopes, and alpha emitters. In 2015, the diagnostic segment is expected to account for the largest share of the North American nuclear medicine market, with the SPECT segment likely to account for the largest share of the diagnostic market. While, beta emitters is expected to account for the largest share of the therapeutic market in 2015.

The North American radiopharmaceuticals market, based on application is segmented into SPECT, PET, and therapeutic applications. The SPECT applications is further segmented into Cardiology, Lymphoma

Thyroid, Neurology, and other SPECT applications, while the PET application is segmented into Oncology, Cardiology, Neurology, and other PET applications. The therapeutic application is classified into Thyroid, Bone Metastasis, Lymphoma, Endocrine Tumors, and other therapeutic applications. In 2015, the cardiology application is expected to account for the largest share of North American radiopharmaceuticals market for SPECT applications. The PET market is likely to be dominated by oncology applications and the therapeutic market is likely to be dominated by thyroid applications.

Factors such as increasing preference for SPECT and PET scans, alpha radioimmunotherapy-based targeted cancer treatment, advances in radiotracers, growing incidence of cancer and CVDs, and rising awareness about the effective use of radiopharmaceuticals in various applications are driving the growth of this market. However, factors such as requirement of high capital investments to limit the procurement of scanners, shorter half-life of radiopharmaceuticals, stringent regulatory guidelines and GMPs, and competition from conventional diagnostic procedures are hindering the growth of this market. Moreover, upcoming radioisotopes, alternative diagnostic radiopharmaceutical solutions, cyclotron-based production, and use of radiopharmaceuticals in neurological applications provide a good opportunity for North American radiopharmaceuticals market. A major challenge to the growth of North American radiopharmaceuticals market is the shutdown of nuclear reactors which is likely to create a gap in the demand and supply of radioisotopes.

On the basis of countries, the North American nuclear medicine market is categorized into U.S., and Canada.

North American Nuclear Medicine Market

Source: Annual Reports, SEC Filings, Organization for Economic Co-operation and Development (OECD) Publications, National Institutes of Health (NIH), World Nuclear Association (WNA), International Atomic Energy Agency (IAEA), Nuclear Regulatory Commission (NRC), Society of Nuclear Medicine and Molecular Imaging (SNMMI), Nuclear Energy Agency (NEA), Canadian Nuclear Association (CNA), American Board of Nuclear Medicine, United States Nuclear Regulatory Commission (U.S. NRC), Nuclear Medicine Associations, Expert Interviews, and MarketsandMarkets Analysis

In 2015, U.S. is poised to account for the largest share of the North American nuclear medicine market, followed by Canada. The U.S. market is slated to grow at the highest CAGR during the forecast period. The major factors driving market growth in U.S. include the focus on domestic production of Mo-99, the approval of new radiopharmaceuticals by the FDA in the U.S., FDA approval for alpha emitter, growing focus on therapeutic nuclear medicine as an alternative treatment in oncology, and growing incidence of thyroid cancer.

Some of the major players in the North American nuclear medicine market include Cardinal Health Inc. (U.S.), Mallinckrodt plc (Ireland), GE Healthcare (U.K.), Lantheus Medical Imaging, Inc. (U.S.), Bayer Healthcare (Germany), Bracco Imaging S.p.A (Italy), Eczacibasi-Monrol Nuclear Products (Turkey), Nordion, Inc. (Canada), Advanced Accelerator Applications S.A. (France), and IBA Molecular Imaging (Belgium).

Custom Market Research Services

We will customize the research for you, in case the report listed above does not meet with your exact requirements. Our custom research will comprehensively cover the business information you require to help you arrive at strategic and profitable business decisions.

Please visit http://www.marketsandmarkets.com/knowledge-process-outsourcing-services.asp to specify your custom Research Requirement

Connect With Us

Follow us on LinkedIn  Follow us on Facebook   Follow us on Twitter 
Live Chat Support


US : 1-888-600-6441
UK : 44-800-368-9399

Search reports